Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Apogee Therapeutics develops therapies for inflammatory autoimmune diseases. Find out why I'm bearish on APGE stock.

Well, we are very excited that we have multiple development in the study of treatment of vasculitis, and this is all because ...

Water bead toys have the potential to cause not only intestinal obstruction in children who ingest them, but also ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

An artificial intelligence model has created a new protein that researchers say would have taken 500 million years to evolve ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...